Sebetralstat

Sebetralstat

Clinical data
Other names	KVD-900
Legal status
Legal status	Investigational
Identifiers
IUPAC name N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide
CAS Number	1933514-13-6
PubChem CID	121365142
IUPHAR/BPS	11947
DrugBank	DB18305
ChemSpider	115006749
UNII	O5ZD2TU2B7
KEGG	D12396
ChEMBL	ChEMBL5095248
Chemical and physical data
Formula	C26H26FN5O4
Molar mass	491.523 g·mol−1
3D model (JSmol)	Interactive image
SMILES COCC1=NN(C=C1C(=O)NCC2=NC=CC(=C2F)OC)CC3=CC=C(C=C3)CN4C=CC=CC4=O
InChI InChI=1S/C26H26FN5O4/c1-35-17-22-20(26(34)29-13-21-25(27)23(36-2)10-11-28-21)16-32(30-22)15-19-8-6-18(7-9-19)14-31-12-4-3-5-24(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,29,34) Key:KGMPDQIYDKKXRD-UHFFFAOYSA-N

Sebetralstat is an investigational new drug that is being evaluated for the treatment of hereditary angioedema. It is a plasma kallikrein inhibitor.